-The Business Standard The move is aimed at having a stringent regulatory system while bringing in uniformity in approach for pricing of drugs  The drug price regulator would now visit manufacturing facilities of pharmaceutical companies while fixing prices of essential medicines. The National Pharmaceutical Pricing Authority (NPPA) has issued internal guidelines putting in place norms for verification of actual cost data, provided by companies, through plant visits.  The move is aimed at...

-The Economic Times MUMBAI: A drug maker found overcharging will have to shell out the entire sales revenue of the medicine from the date of its launch as penalty, according to a directive issued by the country's drug price regulator. "If a company has not been booked for overcharging for selling the product without price approval, if any, pertaining to the period prior to fixation of the price of the said formulation,...

-The Times of India India will, for the first time, put a cap on the maximum price at which essential drugs, like some commonly used anti-AIDS and anti-cancer drugs, besides a horde of painkillers, anti-TB drugs, sedatives, lipid lowering agents and steroids, can be sold in the country. In a landmark decision, a group of ministers (GoM) headed by agriculture minister Sharad Pawar on Thursday cleared the proposal to bring all 348...

-The Economic Times India's drug price regulator has initiated a process to end the 16-year freedom enjoyed by foreign drug makers to fix the retail price of their imported medicines in the country. The National Pharmaceutical Pricing Authority (NPPA) has written to the department of pharmaceuticals to amend the Drugs (Prices Control) Order of 1995, its chairman CP Singh told ET. The amendment will allow NPPA to seek details of the methodology adopted...

-The Business Standard State must get out of insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise insulin prices. Domestic insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...